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Abstract
Background. The Anaesthetic Conserving Device is a modified heat and
moisture exchanger that enables the application of inhalation sedation
with existing ventilators in intensive care units. The following review
describes the advantages of inhalation sedation using the Anaesthetic
Conserving Device in comparison to standard intravenous sedation for
patients in intensive care units and highlights the technical aspects of its
functioning.
Methods. The literature search was limited to PubMed, Sage Journals
and CINAHL databases, using the terms »anaesthetic conserving
device«, »volatile anaesthetic reflection filter«, »AnaConDa«
independently and in connection with the terms »sedation« and
»intensive care unit«. Included are articles published up until December
2014.
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Results. Use of inhalation sedation with the Anaesthetic Conserving
Device enables faster transition to spontaneous breathing and a shorter
awakening time than with intravenous sedation. Even short-term
inhalation sedation of patients after open heart procedures has a
cardioprotective effect and reduces troponin T values. Despite increased
concentrations of inorganic fluoride in serum after sevoflurane exposure,
no clinical studies to date have shown its nephrotoxic effect, even after
long-term (48 h) sedation. The Anaesthetic Conserving Device is
accurate in maintaining target values of volatile anaesthetics. However,
increased dead space volume was found in several studies, exceeding the
internal volume of the Anaesthetic Conserving Device.
Conclusion. Results to date show that inhalation sedation with the
Anaesthetic Conserving Device may be an effective and safe alternative to
existing protocols of intravenous sedation for patients requiring
intensive treatment.
Key words: anaesthetic conserving device, inhalational sedation,
intravenous sedation, intensive care unit
Introduction
Effective sedation and analgesia are indispensable elements of treating
patients in intensive care units (ICU) in order to reduce pain, anxiety,
and agitation during mechanical ventilation and when other invasive
diagnostic and therapeutic interventions are performed. (1,2) Current
guidelines for analgesia and sedation of patients in ICU favour the use of
intravenous forms of sedation. (3) Propofol and midazolam are the most
often used drugs for sedation of critically ill patients; however, the
literature highlights numerous adverse effects of such intravenous
anaesthetics. (4,5)
Compared to most intravenous anaesthetics, volatile anaesthetics, such
as sevoflurane and isoflurane, offer better control of sedation since they
do not accumulate or develop tolerance. Emergence times of patients
sedated by inhalation are therefore shorter and more predictable than
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after intravenous sedation. (6) The end-tidal tension of a volatile
anaesthetic accurately reflects arterial partial pressure, providing a
precise indicator of the volatile anaesthetics partial pressure and
concentration in the central nervous system. (7) Volatile anaesthetics act
primarily on the cerebral cortex, depressing the consciousness and have
analgesic properties even at low concentrations, while leaving many
autonomic functions such as temperature control, blood pressure
regulation or respiration undisturbed. (8) In comparison with
intravenous anaesthetics, they are mainly excreted via the respiratory
system, so only a minor part is metabolised by the liver or kidney. (6) In
humans, the metabolism degrades approximately 0.2 % of isoflurane and
2-5 % of sevoflurane. (9) They have a bronchodilatory effect (10) and
protective properties on numerous organs (above all cardioprotective
and cerebroprotective). (11,12)
Initial attempts at conserving anaesthetic vapours using an open system
involved the development of a reflector that incorporated zeolite crystals.
(13) However, because of the possibility of zeolite inhalation causing
pulmonary toxicity (14), one proposed solution was to use a charcoal
filter instead of a zeolite one. (15) The principle of the charcoal filter was
further developed, leading to the creation of a device for inhalation
sedation AnaConDaTM (Anaesthetic Conserving Device; Sedana Medical,
Uppsala, Sweden), which enables sedation and analgesia of patients in
ICU with isoflurane and sevoflurane. (16)
The Anaesthetic Conserving Device (ACD, AnaConDaTM) is a modified
heat and moisture exchanger, which is inserted between the Y-piece of
the breathing circuit and the endotracheal tube (ET-tube) (figure 1) and
can be used with any type of ICU ventilator (17,18) without a heated
humidifier. The ACD contains active lipophilic carbon fibres, which have
the capacity to bind 90% of the expired volatile anaesthetic. These are
again released with the following inspiratory cycle. Leakage of the
anaesthetic into the environment is thus limited and use of the volatile
anaesthetic is also more economical and safer for medical personnel. The
lost amount of volatile anaesthetic (10%) is replaced by liquid
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anaesthetic, which is uninterruptedly supplied to the equipment by a
standard syringe pump and then through a miniature evaporator rod
vaporises into the breathing gas with which the patient is ventilated.
(8,19) A sampling port located on the patient side of the device allows the
expired gas concentration to be continuously displayed on the gas
monitor (figure 2). (20) Expired gas should be actively or passively
scavenged at the gas outlet of the ventilator. (16) Enlund et al. (17) first
described its clinical use for anaesthesia, and Sackey et al. (21) reported
its safe use for inhalational sedation in ICU patients.
The following review describes the advantages of inhalation sedation
using the ACD in comparison to standard intravenous sedation for
patients in ICU and highlights the technical aspects of the functioning of
the ACD.
Methods
A literature search was conducted using the electronic databases of
PubMed, Sage Journals and the Cumulative Index to Nursing & Allied
Health Literature (CINAHL) using the following terms: “anaesthetic
conserving device”, “volatile anaesthetic reflection filter”, “AnaConDa”;
independently and in connection with terms “sedation” and “intensive
care unit”. The extract of hits was limited in the databases by the
requirements: scientific journals, peer-reviewed articles and entire text.
Works that presented protocols of research, letters to the editor and
works that dealt with the use of the ACD in the operating room were not
included. Thirty-seven articles were found corresponding to the
aforementioned criteria and 29 were retained. We additionally excluded
four review papers. Twenty-five articles that met the criteria were
included in our review. Articles selected for this review were published in
English before December 31, 2014.
Results
Twenty-five articles were included in our review, nine of which are
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randomised clinical studies (table 1), twelve are prospective
observational studies, two case reports and two studies were performed
in a laboratory environment (bench study). Most research into the ACD
has been done in Sweden (8), France (6) and Germany (5). The number
of patients in clinical studies varied from six to 126 patients.
Inhalation sedation with the ACD in ICU – Clinical trials
The majority of clinical studies evaluated the feasibility of inhalation
sedation with the ACD and ascertained its advantages over intravenous
forms of sedation. They primarily compared the awakening time of
patients after sedation, which was assessed as the time from ending
sedation to removal of the ET-tube and the time to an appropriate verbal
response of the patient. The quality of sedation and awakening was
evaluated by assessment of the depth of sedation, stability of the cardio-
vascular system of patients, the occurrence of delusions and
hallucinations, the occurrence of adverse effects, the length of stay in the
ICU and in hospital and an assessment of the costs of sedation and
analgesia in the ICU. Table 1 presents the main findings of randomised
clinical studies that were included in the literature review. The majority
of the studies showed that the awakening time of patients sedated with
volatile anaesthetic using the ACD was shorter than with intravenous
sedation. (21-25) Patients sedated with volatile anaesthetics needed a
shorter period of mechanical ventilation, the ET-tube was removed more
quickly and cognitive functions normalised faster, irrespective of the
length of sedation.
Sackey et al. (21) analysed the influence of prolonged sedation (>12 hrs)
on the awakening time of sedated patients. They compared sedation with
isoflurane with sedation with midazolam in a heterogeneous group of
patients in ICU. The removal of the ET-tube was faster in patients
sedated with volatile anaesthetic (isoflurane: 10 ± 5 min) than in patients
on intravenous sedation (midazolam: 252 ± 271 min); patients after
isoflurane followed simple verbal instructions faster (10 ± 5 min) than
patients after midazolam (110 ± 132 min). Sevoflurane, because of its
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pharmacokinetic properties, provides faster induction and recovery in
comparison with isoflurane. Mesnil et al. (22) analysed patients who
required sedation >24 hrs and compared inhalation sedation with
sevoflurane (n=19) with intravenous sedation with propofol (n=14) or
midazolam (n=14). In addition to faster removal of the ET-tube and a
shorter awakening time of patients sedated with volatile anaesthetic
(sevoflurane: 33.6 ± 13.1 and 18.6 ± 11.8 min) in comparison with the
other two groups on intravenous sedation (propofol: 326.11 ± 360.2 and
91.3 ± 35.2 min; midazolam: 599.6 ± 586.6 and 260.2 ± 150.2 min), the
authors also found a better quality of awakening. Patients were less
agitated and had fewer hallucinations. Studies that dealt with short-term
sedation (<12 hrs) showed similar findings. (23,24)
It is difficult to achieve a suitable depth of sedation with some patients in
ICU using standard protocols of intravenous sedation, so higher doses of
drugs or their combination are required. This can lead to over-deep
sedation of patients and/or haemodynamic instability. L’her et al. (26)
found that in the case of patients that needed higher doses of midazolam
than the average (> 0.05 mg/kg/h) in the first 24 hrs, an appropriate
depth of sedation was achieved faster under inhalational sedation with
isoflurane. The same authors also showed a lower use of analgesics
(sufentanil) in the case of inhalation sedation. A similar opioid sparing
effect of isoflurane was demonstrated in the study by Sackey et al. (21)
Mesnil et al. (22) found that the use of opioid analgesics in the period of
24 hrs after removal of the ET-tube was lower in the group of patients on
inhalation sedation with sevoflurane than in the group that was on
intravenous sedation with propofol or midazolam. Furthermore, the last
recorded pain scores were significantly lower in the group on inhalation
sedation.
The occurrence of adverse effects, such as arrhythmia, diarrhoea, nausea,
vomiting and insufficient respiratory function in patients on inhalation
sedation using the ACD has also been investigated and compared with
intravenous forms of sedation. (21,22,24) Significant differences in the
occurrence of the aforementioned adverse effects between the two forms
of sedation were not established. Studies similarly did not demonstrate
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statistically significant differences between intravenous and inhalation
forms of sedation in the functioning of the circulatory system, liver and
kidneys. (23,24,26,27)
Some concerns still remain about the nephrotoxicity of volatile
anaesthetics because of the formation of fluoride ions. (21,25) Three
studies (22,25,28) ascertained the values of inorganic fluoride in serum
with patients sedated with sevoflurane. Despite increased concentrations
of inorganic fluoride in serum after sevoflurane exposure, glomerular
and tubular renal integrity were preserved in the patients throughout the
hospital stay. Furthermore, Perbet et al. (28) demonstrated that
following 48 hrs of inhalational sevoflurane sedation using the ACD,
washout of sevoflurane was rapid. Marcos-Vidal et al. (29) similarly did
not find any differences in creatinine levels in the serum of patients who
were sedated after cardiac operations with sevoflurane or propofol.
Similar results in relation to the effect of inhalation sedation on renal
function have also been shown for isoflurane. (21)
Volatile anaesthetics cause a widening of the brain blood vessels, which
in turn increases cerebral blood volume and intracranial pressure (ICP).
Bösel et al. (30) analysed the effects of isoflurane on cerebral parameters
in neuromonitored ICU stroke patients and showed that it is possible to
reach sufficient sedation levels in cerebrovascular ICU patients by
applying isoflurane long-term (mean 3.5 days), without a corresponding
increase in ICP, if baseline values of ICP are low to moderately elevated.
Although ICP values were increased by 2.1 mmHg in the first hour after
the transition of patients from an intravenous (with midazolam or
propofol) to an inhalation form of sedation, these remained stable during
the period of observation. However, after transition to inhalation
sedation, a fall in mean arterial pressure and, consequently, cerebral
perfusion pressure, was observed in patients, which required the
additional use of vasopressors. They therefore propose the mandatory
use of extended neuromonitoring of cerebrovascular ICU patients when
sedated with volatile anaesthetics. Furthermore, Villa et al. (31) found
that isoflurane increases regional cerebral blood flow in comparison to
propofol in patients with severe subarachnoid haemorrhage, but the ICP
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values did not change significantly between the two forms of sedation.
The study only included patients (n=13) with normal (<18 mmHg) and
untreated ICP.
Some studies (29,32,33) have assessed whether the administration of
volatile anaesthetics during the post-operative period has beneficial
effects on markers of myocardial injury. Steurer et al. (32) found
significantly lower values of serum troponin T in a group of patients
sedated with sevoflurane (2 hrs) than in a propofol group. Studies by
Marcos-Vidal et al. (29) and Hellström et al. (33) also confirmed that late
postconditioning with sevoflurane might mediate cardiac protection.
Case reports on the use of the ACD in paediatric ICU are also worth
mentioning. Jung et al. (34) reported the use of sevoflurane with the
ACD for the sedation of a 30-month old girl with extensive burns. Sackey
et al. (35) described long-term sedation with isoflurane with three
children in paediatric ICU. In order to minimize the dead space of the
ACD (100 mL) and avoid high end-tidal CO2 concentrations in children
(weighing less than 30 kg), they inserted the ACD in the inspiratory limb
of the breathing circuit. Recirculation of the anaesthetic gas is
deliberately avoided, in a manner requiring a higher infusion rate in
order to maintain the desired concentration of anaesthetic vapour.
The economic aspect of the use of inhalation sedation with the ACD is
also important. Sackey et al. (36) demonstrated a 75 % lower
consumption of volatile anaesthetic with the ACD using high-flow
ventilators in comparison with sedation via standard vaporizers. Two
studies (24,26) compared the costs of intravenous and inhalation
sedation using the ACD. L’her et al. (26) found that inhalation sedation
with isoflurane was less expensive (midazolam: 218 ± 111 EUR;
isoflurane: 110 ± 19 EUR) than average with patients who needed higher
doses of midazolam for achieving a suitable depth of sedation. However,
Röhm et al. (24) stated higher daily costs of sedation (including device-
related equipment) in the case of inhalation sedation (sevoflurane: 65.49
± 10.52 EUR; propofol: 13.38 ± 5.91 EUR per patient). However, no
study has been based on an exact economic analysis and taken into
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account the indirect costs of treatment in ICU, since Röhm et al. (24,25)
showed that patients sedated with volatile anaesthetics have a shorter
ICU and hospital stay.
Technical aspects of inhalation sedation with the ACD
Some studies have focused on the technical aspects of the ACD, such as
the effect of ventilation parameters on ACD performance, the influence
of its internal volume (volume of the dead space) on the patient`s
mechanical ventilation and the level of ambient pollution with volatile
anaesthetics when using the ACD.
Belda et al. (37) demonstrated a high precision of the ACD in
maintaining target concentrations of volatile anaesthetic (1.0 vol% and
1.5 vol%) in ICU patients, with the use of a simplified pharmacokinetic
model for manually adjusted infusion of liquid sevoflurane. Berton et al.
(38) highlighted that ventilation settings (respiratory rate and especially
tidal volume) influence the vapour output of the ACD. The expired
volatile anaesthetic fraction decreased when the tidal volume increased
at a constant infusion flow rate of anaesthetic agent. The influence of
respiratory minute volume on the performance of the ACD was also
confirmed by Meiser et al. (20) They found that the ACD is accurate in
maintaining target values of volatile anaesthetics as long as its reflecting
capacity is not exceeded (10 mL of anaesthetic vapour contained in one
expired breath; e.g., 1 vol% in 1000 mL or 2 vol% in 500 mL, etc.). An
increased minute ventilation therefore necessitates an increased infusion
rate in order to keep the desired concentration of volatile anaesthetic in
the breathing circuit.
Elevated arterial CO2 tension (PaCO2) has been observed in patients
when using the ACD, despite tidal volume compensation. (24,27) The
ACD has an internal volume of approximately 100 mL, which
additionally increases the anatomical dead space in a ventilated patient.
Sturesson et al. (39) argue that use of the ACD increases the apparent
dead space to a greater extent than can be explained by its internal
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volume. In fact, they demonstrated that the ACD adsorbs exhaled CO2,
which is returned during the next inhalation cycle, creating an additional
apparent dead space. In further studies, the same authors found that the
humidity of the gas exhaled by the patient (40) and the presence of
volatile anaesthetic in the breathing circuit (41) reduce the rebreathing of
CO2, although it is still present. A study on patients sedated with
sevoflurane using the ACD showed an 88 mL larger apparent dead space
than with a conventional heat and moisture exchanger (50 mL due to the
larger internal volume of the ACD and 38 mL due to the rebreathing of
CO2). (41) A larger apparent dead space could be significant in patients
with pathological states connected with inefficient oxygen and CO2
exchange, such as patients with acute respiratory distress syndrome
(ARDS), since lung protective ventilation with low tidal volumes is
recommended for them. (27,40) Calculations by Sturesson et al. (41)
showed that with use of the ACD, it may be difficult to maintain
normocapnia in patients with tidal volume <6 mL/kg, even when the
respiratory rate is increased. A recent study by Chabanne et al. (42)
showed that use of the ACD in ICU patients worsens ventilatory
parameters, with significant increases in the work of breathing, minute
ventilation, intrinsic positive end-expiratory pressure and inspiratory
pressure swings. Sevoflurane use via the ACD (for a light-sedation target)
normalizes respiratory parameters, so it might be an alternative method
for sedation in ICU patients, at least during the weaning process with
pressure-support ventilation.
Various studies have ascertained environmental pollution with volatile
anaesthetics using the ACD, since central gas scavenging systems are rare
in ICU. (18) In the European Union, the upper exposure limit for
isoflurane in the workplace is 50 ppm per hour. (43) Studies in ICU have
shown that, with the use of scavenging systems (either active or passive),
values of volatile anaesthetics remain below the aforementioned
permitted limit when they are administered with the ACD. (18,26,36)
Some studies (36,44) have also shown that adequate room air exchanges
per hour without using any form of gas scavenging maintains
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environmental pollution within permitted limits. Djafari Marbini et al.
(44) measured the ambient levels of isoflurane <2 ppm in the vicinity of a
patient’s head and the predicted nursing area with ten room air
exchanges per hour. Stackey et al. (36) looked at ambient isoflurane
pollution utilizing active scavenging and four room air exchanges per
hour, in 15 patients during ICU sedation for 12 – 96 hrs. Five patients in
this study had no active scavenging and relied on room air exchanges
alone. The mean levels of isoflurane pollution were <0.5 ppm in all
patients. Despite the fact that studies show low environmental pollution
with volatile anaesthetics using the ACD, these are based on small
samples and a low number of measurements. Similarly, the conditions
under which pollution with gas anaesthetics was measured were various.
This aspect of the use of the ACD must therefore be additionally studied.
Discussion
The clinical use of inhalation sedation in ICU was described in the late
1980s for patients with bronchial asthma and patients with drug abuse or
addiction syndromes, since in such cases a combination of a variety of
hypnotics and analgesics are required for adequate analgosedation. (19)
With the arrival of the ACD on the market, inhalation sedation in ICU
has been increasingly established in various countries of the European
Union and Canada. (18,20,22,23) Research to date has shown that the
use of inhalation sedation with the ACD in ICU is simple and safe for
both patients and staff. (26,27,37)
The literature included in the review shows that use of inhalation
sedation enables faster transition to spontaneous breathing and removal
of the ET-tube and a shorter awakening time of patients than with
intravenous sedation. (21-23) In addition, patients sedated with volatile
anaesthetics need less analgesics (22,26) and the hospital stay is shorter.
(24,25) Even short-term inhalation sedation of patients after cardiac
operations has a cardioprotective effect and reduces values of troponin T.
(29,32) Similarly, inhalation sedation using the ACD enables direct
control of the concentration of volatile anaesthetic in the breathing
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circuit, so the depth of sedation of a patient can be easily monitored and
titrated. (21,33)
Jackson et al. (45) reported that 33 % to 57 % of patients in ICU do not
receive appropriate drugs and doses that enable suitable analgesia and
depth of sedation. Too-deep sedation and analgesia prolongs the need for
mechanical ventilation and increases the risk of occurrence of
pneumonia and sepsis, (46) increases the risk of haemodynamic
instability, which can prolong the ICU stay and increase the mortality of
patients. (1) Too-shallow sedation and analgesia can cause fear, pain,
stress and anxiety, which increase the level of endogenous
catecholamines, increase the metabolism and use of oxygen, arterial
pressure and incidence of tachyarrhythmia, which can cause additional
complications in the treatment of a critically ill patient. (47)
Although only a minor percentage of isoflurane and sevoflurane is
metabolised by the kidneys because of the formation of fluoride ions,
concerns about their nephrotoxicity are still present. Plasma fluoride
concentrations exceeding 50 μmol/L and the risk of kidney injury have
been described with methoxyflurane. (48) Several studies have found
elevated values of inorganic fluoride more than 50 or 100 μmol/L.
(22,25,28) However, despite increased concentrations of inorganic
fluoride in serum after sevoflurane exposure, glomerular and tubular
renal integrity were preserved in patients (22,25) even after long-term
sedation with sevoflurane. (28) Two factors may explain these
differences between methoxyflurane and sevoflurane: a) it is not the peak
serum fluoride concentration but the duration of the systemic fluoride
that is important. Sevoflurane is less soluble than methoxyflurane in
blood and tissues; sevoflurane thus exits the body much more rapidly;
and b) the liver is the primary organ of metabolism of sevoflurane,
whereas both the liver and kidney metabolize methoxyflurane. (49) The
high local (intrarenal) production of fluoride ions from methoxyflurane
probably explains the greater capacity of that anaesthetic to produce
renal injury from fluoride production. This is in agreement with several
studies in which no differences in creatinine levels in the serum of
patients who were sedated with sevoflurane, propofol or isoflurane were
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reported. (21,29)
Despite the large number of studies investigating the use of inhalation
sedation with the ACD in adult patients, almost no research has been
carried out on the use of inhalation sedation in critically ill children. It is
well known that optimal sedation in critically ill children is often difficult
to achieve due to the altered pharmacokinetics and dynamics in children.
Tolerance and withdrawal after long-term benzodiazepine use in
paediatric ICU has been described. (50) Furthermore, some studies have
shown the clinical usefulness of volatile anaesthetics for sedation in
children. (51,52) To date, only a few case reports have described
inhalation sedation with ACD in paediatric ICU with encouraging results
(34,35), and further evaluation of the usefulness of this method of
sedation for paediatric patients is still needed.
In adult patients without pulmonary pathology, the additional dead
space of the ACD can be considered clinically unimportant, although
some studies have identified increased values of PaCO2 in patients.
(24,27) Values of PaCO2 were therefore balanced with higher tidal
volumes and/or respiratory rates. Sturesson et al. (41) demonstrated
that, with the use of the ACD, normocapnia may be difficult to maintain
when using a low tidal volume, even when the respiratory rate is
increased. This might limit the usefulness of ACD in clinical settings. In
fact, lung protective ventilation (mechanical ventilation with low
respiratory volumes, ≤ 6 mL/kg), is of key importance and an integral
part of treatment of patients with ARDS. (53) However, hypercapnia is a
central component of current protective ventilatory strategies. Increasing
clinical evidence supports the use of permissive hypercapnia, particularly
in acute lung injury/ARDS, status asthmaticus, chronic obstructive
pulmonary disease and neonatal respiratory failure, in order to avoid the
deleterious effects of high lung stretch. (54) Additionally, with
inhalational sedation, spontaneous breathing can be maintained and, if
necessary, may be augmented by various ventilator modes. (8,42)
Although some authors (27,41) argue that the use of the ACD might not
be appropriate for patients with respiratory diseases with increased
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physiological dead space and/or ventilation difficulties, there are still no
clear guidelines or research in this field. According to the manufacturer’s
instructions, the use of the ACD is advised only in patients with a tidal
volume >350 mL. (8)
Conclusion
Because of their pharmacokinetic properties, use of volatile anaesthetics
with ICU patients is becoming increasingly interesting, especially for
some groups of critically ill patients. With the arrival of the ACD, their
use in ICU has finally become available. However, the number of
prospective randomised clinical studies investigating the effectiveness
and safety of inhalation sedation of ICU patients using the ACD is
relatively small. We also highlighted some issues that are still unclear
(the influence of the ACD dead space on patient ventilation, gas
scavenging, the cost of inhalation sedation with ACD etc.) and need to be
additionally explored. Otherwise, the results to date show that inhalation
sedation with the ACD can be a useful alternative to existing protocols of
intravenous sedation of patients requiring intensive treatment.
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Figure 1. Connection of the AnaConDa (arrow) to the ventilator circuit
on high-fidelity simulator.
Figure 2. AnaConDa system components: 1 AnaConDa device, 2 Agent
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supply line with valve and screw cap, 3 Gas measurement port, 4
AnaConDa syringe with screw coupling and screw cap.
Table 1. Randomised clinical studies of inhalation sedation using the
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discharge
ACD, AnaConDa; ET-tube, endotracheal tube; I, isoflurane; ICU,
intensive care unit; M, midazolam; min, minimum; P, propofol; S,
sevoflurane.
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